Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

globenewswire.com
NVO Novo Nordisk is experiencing strong growth driven by the successful launch and rapid adoption of its Wegovy pill, leading to raised guidance for sales and operating profit. Multiple approvals for Wegovy HD further strengthen the portfolio.

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026 Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026

Financial performance

Commercial highlights

Pipeline progress

Outlook

“Wegovy ® is driving a strong start to 2026 for Novo Nordisk, led by the rapid adoption of Wegovy ® pill - the most efficacious GLP-1 tablet now used by more than one million patients since its January launch. As the global momentum behind peptide-based therapies accelerates, Wegovy ® pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for what patients and physicians can expect. The strong Wegovy ® performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit,” said Mike Doustdar, president and CEO of Novo Nordisk. “During the quarter, we also secured multiple approvals for Wegovy ® HD, strengthening the Wegovy ® portfolio, and enabling patients to achieve nearly 21% weight loss.”

On 6 May 2026 at 13.00 CEST, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K).

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.

Company announcement No 30 / 2026

Attachment